A 10-year-old spayed female German Shepherd presents with...

Hello. Thank you for reaching out about this 10-year-old German Shepherd. The presentation of progressive PU/PD and weight loss, coupled with azotemia, an elevated SDMA of 28 µg/dL, and a USG of 1.012, strongly indicates significant chronic kidney disease (CKD). An SDMA of 28 µg/dL, along with azotemia, places this patient in at least IRIS Stage III CKD, which is a critical piece of information for drug dosing.

Regarding metronidazole, it is primarily metabolized by the liver, but a significant portion of the drug (around 10-20%) and its active metabolites are excreted renally. In patients with advanced renal impairment, such as your German Shepherd with Stage III CKD, there's a risk of accumulation of the drug and its metabolites. This accumulation can increase the likelihood of adverse effects, particularly neurotoxicity, which can manifest as ataxia, nystagmus, seizures, or tremors.

Based on our formulary, the standard dose for metronidazole in dogs is 10-15 mg/kg PO BID. For patients with IRIS Stage III or IV CKD, it is prudent to adjust this dosage to minimize the risk of drug accumulation and neurotoxicity.

My recommendation for safe dosing in this patient would be to reduce the frequency of administration to once daily (q24h) while keeping the dose within the lower end of the therapeutic range. Therefore, I would suggest:

* Metronidazole: 10 mg/kg PO q24h.

This adjustment aims to maintain therapeutic levels while allowing for more complete renal clearance between doses, thereby reducing the risk of accumulation.

Important considerations:

Monitor for Neurotoxicity: Even with dose adjustments, vigilance for signs of neurotoxicity (e.g., ataxia, disorientation, head tilt, nystagmus, tremors, seizures) is crucial. If any of these signs develop, discontinue the metronidazole immediately.

Therapeutic Rationale: Always ensure there's a clear indication for metronidazole use. While it's commonly used for anaerobic infections and certain GI inflammatory conditions, it's essential to confirm its necessity, especially in a patient with compromised renal function. If GI signs are the primary reason for considering metronidazole, I would want to ensure we've explored other potential causes of GI upset in a CKD patient, such as uremic gastritis or imbalances in the gut microbiome.

Hydration Status: Maintaining adequate hydration is paramount in CKD patients, and particularly when administering renally excreted drugs. Ensure the patient is well-hydrated.

High confidence in this dose adjustment recommendation, given the patient's IRIS Stage III CKD. Please let me know if you have further questions about the underlying CKD management or other aspects of this case.